SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biosource International

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: BULL who wrote (182)8/29/1997 6:36:00 PM
From: Douglas V. Fant   of 696
 
Bull,

Clearly no guarantees- small cap stocks such as these are always risky; but here's a little information which I gleaned off of the Zack's Subscription Service on BIOI:

(1) A Brokerage Report: On March 7, 1997 Wedbush Morgan Securities analyst Alexander Arrow issued a 13 page Company Report on BIOSOURCE INTL. Report highlights: " Coverage was initiated with a BUY rating as the company appears positioned to benefit from the growing number of new biotech companies, and the changing structure of large pharmaceutical companies. "

Alexander Arrow is ranked 4 out of 5 when predicting changes in stock prices for Biosource International, Inc.

Alexander Arrow has not made enough EPS forecasts to be meaningfully ranked relative to 4 other analysts following the same company. (Four analysts, all small brokerage houses, rate BIOI a "buy", while one company rates BIOI a "neutral", over the last threee months or so...).

(2) Three analysts have estimated FY 98 earnings raning from $.46/share to $.69/share with the mean estimate being $.66/ share. The projected 5-year growth rate of revenues is estimated by Zack's to be 37.5% annually, with it being a tad lower about 35% in 1997.

Next earnings report is estimated to come out on October 21, 1997 currently....
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext